亚虹医药(688176.SH)：前三季度净亏损2.49亿元

Core Insights - The company achieved a total operating revenue of 216 million yuan in the first three quarters of 2025, representing a year-on-year increase of 55.74% [1] - The net profit attributable to shareholders of the parent company was -249 million yuan, which is a reduction in losses by 21.89 million yuan compared to the same period last year [1] - The basic earnings per share stood at -0.44 yuan [1]